Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
October 21, 2024 13:04 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
October 21, 2024 04:00 ET
|
Oculis Holding AG
Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If...
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
October 15, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
October 02, 2024 04:00 ET
|
Oculis Holding AG
Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis’...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
October 02, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device...
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
September 19, 2024 13:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in...
Oculis to Present at Upcoming September Investor Conferences
August 29, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Publishes Consolidated Q2 Financial Statements and MD&A
August 27, 2024 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been...
Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
August 27, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Sviss, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Félagið birti jákvæðar niðurstöður fyrir fasa 2b RELIEF rannsóknina á OCS-02 (licaminlimab) sem rennir stoðum undir möguleika á fyrstu...
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
August 27, 2024 04:00 ET
|
Oculis Holding AG
Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of...